We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma

This study has suspended participant recruitment.
(Company at this time unable to secure sufficient financial resources to complete)
Sponsor:
ClinicalTrials.gov Identifier:
NCT02546102
First Posted: September 10, 2015
Last Update Posted: June 23, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Novella Clinical
Information provided by (Responsible Party):
ImmunoCellular Therapeutics, Ltd.
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has suspended participant recruitment.
  Estimated Study Completion Date: December 2021
  Estimated Primary Completion Date: December 2019 (Final data collection date for primary outcome measure)
Publications: